Home » Stocks » OXFD

Oxford Immunotec Global PLC (OXFD)

Stock Price: $21.96 USD 0.01 (0.05%)
Updated Mar 1, 2021 4:00 PM EST - Market closed
Market Cap 561.69M
Revenue (ttm) 57.30M
Net Income (ttm) -17.48M
Shares Out 25.90M
EPS (ttm) -0.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $21.96
Previous Close $21.95
Change ($) 0.01
Change (%) 0.05%
Day's Open 21.97
Day's Range 21.96 - 22.00
Day's Volume 174,332
52-Week Range 8.37 - 23.11

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 week ago

Oxford Immunotec (OXFD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 3 weeks ago

OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today ann...

GlobeNewsWire - 3 weeks ago

OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today an...

GlobeNewsWire - 1 month ago

The first survey results reveal physicians seek new diagnostic tools and insights to improve COVID-19 management and patient outcomes The first survey results reveal physicians seek new diagno...

GlobeNewsWire - 1 month ago

OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, announce...

Business Wire - 1 month ago

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether Oxford Immunotec Global PLC (NASDAQ: OXFD) and its board of directors violated the fede...

The Motley Fool - 1 month ago

Investors cheered PerkinElmer's acquisition of the diagnostics company.

Investors Business Daily - 1 month ago

Oxford Immunotec Global shares surged Thursday after PerkinElmer agreed to buy the diagnostics-focused medical stock for $591 million. This follows its plan to buy Horizon Discovery.

Other stocks mentioned: PKI
Business Wire - 1 month ago

WALTHAM, Mass. & LONDON--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Oxford Immunotec Global PLC (NASDAQ: OXFD) ("Oxford Immunotec" or the “Company”) are pleased to anno...

Other stocks mentioned: PKI
GlobeNewsWire - 2 months ago

OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, announce...

GlobeNewsWire - 2 months ago

OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today ann...

GlobeNewsWire - 2 months ago

OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today ann...

GlobeNewsWire - 3 months ago

OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today ann...

GlobeNewsWire - 3 months ago

OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today an...

GlobeNewsWire - 3 months ago

If approved, the T-Cell Select reagent kit would enable automated sample preparation and the T-SPOT®.TB test to be used with blood samples stored for up to 54 hours at room temperature

Seeking Alpha - 3 months ago

Oxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 50.00% and 4.61%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the s...

GlobeNewsWire - 3 months ago

OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global diagnostics company, today announced third...

GlobeNewsWire - 4 months ago

OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today an...

GlobeNewsWire - 4 months ago

OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today ann...

GlobeNewsWire - 5 months ago

The T-SPOT.TB test is now the only interferon-gamma release assay (IGRA) cleared for use in children ages two and upwards in the United States The T-SPOT.TB test is now the only interferon-gam...

GlobeNewsWire - 5 months ago

OXFORD, United Kingdom and MARLBOROUGH, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today...

Seeking Alpha - 6 months ago

Oxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of -428.57% and -4.19%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 6 months ago

OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global diagnostics company, today announced sec...

Zacks Investment Research - 7 months ago

Oxford Immunotec (OXFD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 7 months ago

OXFORD, United Kingdom and MARLBOROUGH, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today a...

GlobeNewsWire - 7 months ago

OXFORD, United Kingdom and MARLBOROUGH, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), today announced that it has entered into a long-te...

Seeking Alpha - 9 months ago

Oxford Immunotec Global PLC's (OXFD) CEO Peter Wrighton-Smith on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of -185.71% and -1.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the st...

Benzinga - 9 months ago

Shares of Oxford Immunotec Global (NASDAQ:OXFD) remained unaffected at $11.76 after the company reported Q1 results.

GlobeNewsWire - 10 months ago

OXFORD, United Kingdom and MARLBOROUGH, Mass., April 21, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced that ...

Seeking Alpha - 11 months ago

Oxford Immunotec Global PLC's (OXFD) CEO Peter Wrighton-Smith on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 45.45% and 4.80%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the st...

GlobeNewsWire - 1 year ago

OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today a...

Zacks Investment Research - 1 year ago

Oxford Immunotec Global is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Seeking Alpha - 1 year ago

Oxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 180.00% and 4.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the ...

Zacks Investment Research - 1 year ago

Oxford Immunotec (OXFD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), or the Company, a global, high-growth diagnostics company, today a...

Zacks Investment Research - 1 year ago

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 140.00% and 0.76%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

Oxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 70.00% and 6.57%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Oxford Immunotec (OXFD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research - 1 year ago

Oxford Immunotec Global PLC (OXFD) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Zacks Investment Research - 1 year ago

Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 757.89% and -17.43%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the...

About OXFD

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis; and reagents and meth... [Read more...]

Industry
Diagnostics & Research
IPO Date
Nov 22, 2013
CEO
Peter Wrighton-Smith
Employees
273
Stock Exchange
NASDAQ
Ticker Symbol
OXFD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for OXFD stock is "Buy." The 12-month stock price forecast is 22.50, which is an increase of 2.46% from the latest price.

Price Target
$22.50
(2.46% upside)
Analyst Consensus: Buy